Ganoderma lucidum and hericium erinaceus compound formula with stomach health-care function and preparation method of ganoderma lucidum and hericium erinaceus compound formula

Abstract

The invention discloses a ganoderma lucidum and hericium erinaceus composite formula with a stomach health-care function and a preparation method of the ganoderma lucidum and hericium erinaceus composite formula. The ganoderma lucidum and hericium erinaceus composite formula is prepared from the following raw materials in parts by weight: 10 to 20 parts of ganoderma lucidum extract, 15 to 25 parts of hericium erinaceus extract, 8 to 15 parts of pachymaran, 5 to 10 parts of tremella aurantialba polysaccharide, 20 to 30 parts of small molecular protein peptide and 10 to 20 parts of maltose. According to the formula disclosed by the invention, stomach health care is realized through quadruple synergy of protection, repair, regulation and nutrition; hericium erinaceus beta-glucan and pachymaran construct a physical barrier, and ganoderma triterpenes inhibit injury factors; the micromolecular protein peptide provides raw materials, and the tremella aurantialba polysaccharide promotes cell proliferation and accelerates wound healing; the compound polysaccharide and the ganoderma triterpenes synergistically regulate the balance of immunity and inflammation and improve the stomach microenvironment; the small molecule peptide and the maltose supplement energy and nutrition, and the problem of nutrition deficiency of chronic stomach diseases is solved; through reasonable compatibility of all the components, auxiliary improvement on stomach discomfort such as acute and chronic gastritis and gastric ulcer is finally achieved, meanwhile, gastric mucosal lesion is prevented, and normal physiological functions of the stomach are maintained.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine formulation technology, specifically to a compound formulation of Ganoderma lucidum and Hericium erinaceus with stomach health function and its preparation method. Background Technology

[0002] With the fast pace of modern life, diversified dietary structures, and increased mental stress, stomach health problems have become a common concern affecting national health. Statistics show that over 300 million people in my country suffer from stomach diseases, with the incidence of chronic gastritis, gastric ulcers, and gastric mucosal damage rising year by year and showing a trend towards affecting younger people. Poor dietary habits (such as high-oil, high-salt, and spicy foods), Helicobacter pylori infection, prolonged mental stress, and misuse of nonsteroidal anti-inflammatory drugs (NSAIDs) can all lead to damage to the gastric mucosal barrier, imbalance in gastric acid secretion, and decreased gastric immune function, thus causing stomach discomfort. Currently available stomach health products have the following limitations:

[0003] Single ingredient composition: These products are mostly based on single plant extracts (such as Hericium erinaceus powder and Ganoderma lucidum powder) or nutrients (such as proteins and vitamins), making it difficult to achieve synergistic protection against multiple targets. For example, while Hericium erinaceus preparations can promote mucosal repair, they lack anti-inflammatory and immunomodulatory effects; Ganoderma lucidum products focus on immune enhancement and have limited ability to directly repair mucosa.

[0004] Low bioavailability: Natural polysaccharides are difficult to be absorbed by the gastrointestinal tract due to their large molecular weight and poor water solubility; fat-soluble components such as Ganoderma triterpenes are easily destroyed by gastric acid, which limits the actual efficacy of the drug.

[0005] Process defects: Most products use simple mixing or ordinary pulverization processes without optimizing for the stability and synergy of active ingredients. For example, polysaccharides are not enzymatically activated, making it difficult to release the active ingredients; there is a lack of targeted delivery technology, and active ingredients are easily degraded in the stomach.

[0006] Functional limitations: Existing products mostly focus on a single aspect of "repair" or "protection", and cannot meet multiple needs such as strengthening the gastric mucosal barrier, inhibiting inflammation, supplementing nutrition and regulating the microenvironment.

[0007] Therefore, developing a multi-component synergistic, highly bioavailable, and fully functional stomach health formula has become an urgent need to address current stomach health problems. Summary of the Invention

[0008] To solve the above-mentioned technical problems, the technical solution provided by the present invention is: a compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health care function, composed of the following raw materials in parts by weight:

[0009] 10-20 parts of Ganoderma lucidum extract, 15-25 parts of Hericium erinaceus extract, 8-15 parts of Poria cocos polysaccharide, 5-10 parts of Auricularia auricula polysaccharide, 20-30 parts of small molecule protein peptides, and 10-20 parts of maltose;

[0010] Wherein: the Ganoderma lucidum extract contains ≥12% Ganoderma lucidum triterpenes; the Hericium erinaceus extract contains ≥92.7% β-glucan; and the small molecule protein peptide is a whey protein hydrolysate with a molecular weight ≤3kDa.

[0011] Preferably, the weight ratio of Ganoderma lucidum extract to Hericium erinaceus extract is 1:1 to 2; the weight ratio of total complex polysaccharide to small molecule protein peptide is 1:0.5 to 2.0; wherein the total complex polysaccharide is the sum of Poria cocos polysaccharide, Auricularia auricula-judae polysaccharide and β-glucan in Hericium erinaceus extract.

[0012] Preferably, the dosage form is granules, and the moisture content of the granules is ≤5%, and the particle size passes through a 16-mesh sieve.

[0013] Preferably, the method for preparing a compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health benefits includes the following steps:

[0014] (1) Preparation of Ganoderma lucidum extract:

[0015] The fruiting bodies of Ganoderma lucidum were crushed to 60 mesh and extracted twice by reflux with 70% ethanol. The filtrates were combined and concentrated under reduced pressure to obtain an atomized liquid with a Ganoderma lucidum triterpenoid concentration of ≥12%.

[0016] (2) Preparation of Hericium erinaceus extract:

[0017] Hericium erinaceus was freeze-dried to a moisture content of ≤5% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain Hericium erinaceus extract with a β-glucan purity of ≥92.7%.

[0018] (3) Synergistic activation by complex polysaccharides:

[0019] The Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide obtained in step (2) were mixed and added to sodium citrate buffer solution with pH=5.4. Enzymatic hydrolysis was carried out at 45℃ using cellulase and pectinase. After enzymatic hydrolysis, the polysaccharide was inactivated and spray-dried to obtain a composite polysaccharide powder with a water content of ≤3%.

[0020] (4) Microencapsulation coupling:

[0021] The small molecule protein peptides, the composite polysaccharide powder obtained in step (3), and the Ganoderma lucidum extract atomized liquid obtained in step (1) were microencapsulated in a fluidized bed, with an encapsulation rate ≥85%.

[0022] (5) Granulation: The microencapsulated complex obtained in step (4) is mixed with maltose solution to form granules, dried and then granulated to obtain granules.

[0023] Preferably, in step (3), the enzymatic hydrolysis conditions are: 1.5 U / g substrate is added for each of cellulase and pectinase, and the enzymatic hydrolysis time is 120 minutes; the spray drying parameters are: inlet air temperature 180±5℃, outlet air temperature 80±5℃.

[0024] Preferably, the fluidized bed parameters in step (4) are: inlet air temperature 50±2℃, air velocity 1.5±0.2m / s, spray pressure 0.8±0.1MPa; after microencapsulation, the encapsulation rate is detected by microcolumn centrifugation at 3000rpm×10min.

[0025] In this invention, Ganoderma lucidum extract can reduce the erosion of the gastric mucosa by gastric acid by inhibiting the excessive activity of enzymes related to gastric mucosal damage; at the same time, it can promote the synthesis of prostaglandin E2 (PGE2) by gastric mucosal epithelial cells, thereby enhancing the defensive function of the mucosal barrier; it can inhibit the release of inflammatory factors (such as TNF-α and IL-6), thereby alleviating chronic inflammation of the gastric mucosa caused by Helicobacter pylori infection or stress, and reducing the risk of gastritis and gastric ulcers; it can also enhance the local immune function of the gastrointestinal tract by activating immune cells such as macrophages and T lymphocytes, thereby reducing the invasion of pathogens into the gastric mucosa.

[0026] Hericium erinaceus extract can promote the proliferation of gastric mucosal epithelial cells and collagen synthesis, accelerating the healing of gastric ulcers; it also increases gastric mucus secretion, forming a physical barrier to resist damage from gastric acid and digestive enzymes; it can clear excessive reactive oxygen species in the gastric mucosa, reduce the level of lipid peroxidation products, and alleviate the damage of oxidative stress to mucosal cells; it can also improve the gastric microenvironment by promoting the proliferation of beneficial bacteria such as Bifidobacteria and inhibiting the colonization of pathogenic bacteria such as Helicobacter pylori.

[0027] Poria cocos polysaccharides can promote the thickening of the intestinal mucus layer and, together with Hericium erinaceus β-glucan, strengthen the physical barrier of the gastric mucosa; Auricularia auricula polysaccharides reduce the penetration of harmful substances by enhancing the tight junctions between mucosal cells.

[0028] All three polysaccharides can activate the Toll-like receptor (TLR4) signaling pathway, promote the secretion of anti-inflammatory cytokines (IL-10), and inhibit mucosal damage caused by excessive immune response.

[0029] Small molecule protein peptides provide amino acid raw materials for gastric mucosal cells, promote protein synthesis at damaged sites, and accelerate mucosal repair; at the same time, they replenish energy and improve nutrient absorption disorders caused by chronic gastritis; they can also reduce the release of inflammatory factors by inhibiting the activation of nuclear factor κB (NF-κB) pathway, and form an anti-inflammatory synergy with Ganoderma lucidum triterpenes to reduce mucosal redness, swelling and erosion.

[0030] Maltose reduces the stimulation of gastric acid on damaged mucosa through gentle osmotic pressure regulation; at the same time, it provides carbohydrate energy to gastric mucosal cells, assisting in the repair process; its viscous properties can slow down the release rate of other active ingredients in the stomach, prolong the duration of action, and improve the bioavailability of Ganoderma triterpenes, polysaccharides, etc.

[0031] In addition, the enzymatic activation of the complex polysaccharide in the preparation method, and the targeted hydrolysis of cellulase and pectinase can break the glycosidic bonds between polysaccharide molecules, reduce the molecular weight and expose more active groups (such as hydroxyl groups), enhance its binding ability with mucosal cells, and improve barrier protection and immune regulation efficiency.

[0032] Microencapsulation coupling: Fluidized bed microencapsulation enables Ganoderma lucidum extract, complex polysaccharides and small molecule peptides to form a stable core-shell structure, avoiding the destruction of active ingredients (such as Ganoderma lucidum triterpenes) by gastric acid, ensuring precise release after reaching the intestine, and improving targeting and bioavailability.

[0033] The advantages of this invention compared to the prior art are:

[0034] This invention's formula achieves stomach health through a four-pronged synergistic approach of "protection, repair, regulation, and nutrition": Hericium erinaceus β-glucan and Poria cocos polysaccharides construct a physical barrier, while Ganoderma lucidum triterpenes inhibit damaging factors; small molecule protein peptides provide raw materials, and Auricularia auricula-judae polysaccharides promote cell proliferation and accelerate wound healing; the complex polysaccharides and Ganoderma lucidum triterpenes synergistically regulate immune and inflammatory balance, improving the gastric microenvironment; small molecule peptides and maltose supplement energy and nutrition, addressing the nutritional deficiencies in chronic gastritis; through the rational combination of each component, this invention ultimately achieves auxiliary improvement of stomach discomfort such as acute and chronic gastritis and gastric ulcers, while preventing gastric mucosal damage and maintaining normal gastric physiological function. Detailed Implementation

[0035] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. The components of the embodiments of the present invention described and shown herein can generally be arranged and designed in various different configurations.

[0036] Example 1

[0037] A compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health benefits is composed of the following ingredients in parts by weight:

[0038] 15 parts of Ganoderma lucidum extract (12.5% ​​Ganoderma lucidum triterpenoid content), 20 parts of Hericium erinaceus extract (93.0% purity of β-glucan), 10 parts of Poria cocos polysaccharide, 7 parts of Auricularia auricula polysaccharide, 25 parts of small molecule protein peptides (whey protein hydrolysate with a molecular weight ≤3kDa), and 15 parts of maltose.

[0039] The weight ratio of Ganoderma lucidum extract to Hericium erinaceus extract was 1:1.33; the weight ratio of total polysaccharide to small molecule protein peptide was 1:0.70.

[0040] Its preparation method includes the following steps:

[0041] (1) Preparation of Ganoderma lucidum extract: Ganoderma lucidum fruiting body was crushed to 60 mesh, extracted twice by reflux with 70% ethanol, the filtrates were combined and concentrated under reduced pressure to obtain atomized liquid with a Ganoderma lucidum triterpenoid concentration of 12.5%.

[0042] (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of 4.5% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain an extract with a β-glucan purity of 93.0%.

[0043] (3) Synergistic activation of complex polysaccharides: Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide were mixed and added with sodium citrate buffer at pH 5.4. At 45°C, 1.5 U / g of cellulase and pectinase were added as substrates and enzymatically hydrolyzed for 120 minutes. After inactivation, the mixture was spray-dried at an inlet air temperature of 180°C and an outlet air temperature of 80°C to obtain complex polysaccharide powder with a water content of 2.8%.

[0044] (4) Microencapsulation coupling: Small molecule protein peptides, compound polysaccharide powder, and Ganoderma lucidum extract atomized liquid are treated in a fluidized bed with an inlet air temperature of 50℃, an air velocity of 1.5m / s, a spray pressure of 0.8MPa, and an encapsulation rate of 86%.

[0045] (5) Granulation: The microencapsulated complex is mixed with maltose solution and granulated. After drying, the granules are sized to obtain granules (moisture content 4.2%, particle size passing through a 16-mesh sieve).

[0046] Example 2

[0047] A compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health benefits is composed of the following ingredients in parts by weight:

[0048] 10 parts of Ganoderma lucidum extract (Ganoderma lucidum triterpenoid content 12.0%), 18 parts of Hericium erinaceus extract (β-glucan purity 92.7%), 8 parts of Poria cocos polysaccharide, 5 parts of Auricularia auricula polysaccharide, 20 parts of small molecule protein peptides (whey protein hydrolysate with molecular weight ≤3kDa), and 10 parts of maltose.

[0049] The weight ratio of Ganoderma lucidum extract to Hericium erinaceus extract was 1:1.8; the weight ratio of total complex polysaccharides to small molecule protein peptides was approximately 1:0.67.

[0050] Its preparation method includes the following steps:

[0051] (1) Preparation of Ganoderma lucidum extract: Ganoderma lucidum fruiting body was crushed to 60 mesh, extracted twice by reflux with 70% ethanol, the filtrates were combined and concentrated under reduced pressure to obtain atomized liquid with a Ganoderma lucidum triterpenoid concentration of 12.0%.

[0052] (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of 5.0% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain an extract with a β-glucan purity of 92.7%.

[0053] (3) Synergistic activation of complex polysaccharides: Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide were mixed and added with sodium citrate buffer at pH 5.4. Cellulase and pectinase were added at 45°C and enzymatically hydrolyzed for 120 minutes. The mixture was then spray-dried at an inlet air temperature of 175°C and an outlet air temperature of 75°C to obtain complex polysaccharide powder with a water content of 2.5%.

[0054] (4) Microencapsulation coupling: Fluidized bed parameters: inlet air temperature 48℃, air velocity 1.3m / s, spray pressure 0.7MPa, encapsulation rate 85%.

[0055] (5) Granulation: granules are obtained with a moisture content of 4.8% and a particle size that passes through a 16-mesh sieve.

[0056] Example 3

[0057] A compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health benefits is composed of the following ingredients in parts by weight:

[0058] 20 parts of Ganoderma lucidum extract (Ganoderma lucidum triterpenoid content 13.0%), 25 parts of Hericium erinaceus extract (β-glucan purity 94.0%), 15 parts of Poria cocos polysaccharide, 10 parts of Auricularia auricula polysaccharide, 30 parts of small molecule protein peptides (whey protein hydrolysate with molecular weight ≤3kDa), and 20 parts of maltose.

[0059] The ratio of Ganoderma lucidum extract to Hericium erinaceus extract is 1:1.25; the ratio of total complex polysaccharide (25×94.0%+15+10=48.5 parts) to small molecule protein peptides is approximately 1:0.62.

[0060] Its preparation method includes the following steps:

[0061] (1) Preparation of Ganoderma lucidum extract: Ganoderma lucidum fruiting body was crushed to 60 mesh, extracted twice by reflux with 70% ethanol, the filtrates were combined and concentrated under reduced pressure to obtain atomized liquid with a Ganoderma lucidum triterpenoid concentration of 13.0%.

[0062] (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of 4.0% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain an extract with a β-glucan purity of 94.0%.

[0063] (3) Synergistic activation of complex polysaccharides: Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide were mixed and added with sodium citrate buffer at pH 5.4. Cellulase and pectinase were added at 45°C and enzymatically hydrolyzed for 120 minutes. The mixture was then spray-dried at an inlet air temperature of 185°C and an outlet air temperature of 85°C to obtain complex polysaccharide powder with a water content of 2.2%.

[0064] (4) Microencapsulation coupling: The fluidized bed parameters are: inlet air temperature 52℃, air velocity 1.7m / s, spray pressure 0.9MPa, and encapsulation rate 88%.

[0065] (5) Granulation: granules are obtained with a moisture content of 3.8% and a particle size that passes through a 16-mesh sieve.

[0066] Comparative Example 1

[0067] The composition of this comparative formula is as follows:

[0068] 15 parts of Ganoderma lucidum extract (Ganoderma lucidum triterpenoid content 10.0%), 20 parts of Hericium erinaceus extract (β-glucan purity 90.0%), 10 parts of Poria cocos polysaccharide, 7 parts of Auricularia auricula polysaccharide, 25 parts of small molecule protein peptides, and 15 parts of maltose.

[0069] Its preparation method includes the following steps:

[0070] (1) Preparation of Ganoderma lucidum extract: Ganoderma lucidum fruiting body was crushed to 60 mesh, extracted twice by reflux with 70% ethanol, the filtrates were combined and concentrated under reduced pressure to obtain atomized liquid with a Ganoderma lucidum triterpenoid concentration of 12.5%.

[0071] (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of 4.5% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain an extract with a β-glucan purity of 93.0%.

[0072] (3) Synergistic activation of complex polysaccharides: Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide were mixed and added with sodium citrate buffer at pH 5.4. At 45°C, 1.5 U / g of cellulase and pectinase were added as substrates and enzymatically hydrolyzed for 120 minutes. After inactivation, the mixture was spray-dried at an inlet air temperature of 180°C and an outlet air temperature of 80°C to obtain complex polysaccharide powder with a water content of 2.8%.

[0073] (4) Microencapsulation coupling: Small molecule protein peptides, compound polysaccharide powder, and Ganoderma lucidum extract atomized liquid are treated in a fluidized bed with an inlet air temperature of 50℃, an air velocity of 1.5m / s, a spray pressure of 0.8MPa, and an encapsulation rate of 86%.

[0074] (5) Granulation: The microencapsulated complex is mixed with maltose solution and granulated. After drying, the granules are sized to obtain granules (moisture content 4.2%, particle size passing through a 16-mesh sieve).

[0075] Comparative Example 2

[0076] The composition of this comparative formula is as follows:

[0077] 15 parts of Ganoderma lucidum extract (12.5% ​​Ganoderma lucidum triterpenoid content), 20 parts of Hericium erinaceus extract (93.0% purity of β-glucan), 10 parts of Poria cocos polysaccharide, 7 parts of Auricularia auricula polysaccharide, 25 parts of small molecule protein peptides (whey protein hydrolysate with a molecular weight ≤3kDa), and 15 parts of maltose.

[0078] The weight ratio of Ganoderma lucidum extract to Hericium erinaceus extract was 1:1.33; the weight ratio of total polysaccharide to small molecule protein peptide was 1:0.70.

[0079] Its preparation method includes the following steps:

[0080] (1) Preparation of Ganoderma lucidum extract: Ganoderma lucidum fruiting body was crushed to 60 mesh, extracted twice by reflux with 70% ethanol, the filtrates were combined and concentrated under reduced pressure to obtain atomized liquid with a Ganoderma lucidum triterpenoid concentration of 12.5%.

[0081] (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of 4.5% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain an extract with a β-glucan purity of 93.0%.

[0082] (3) Microencapsulation coupling: Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide were mixed in a fluidized bed for treatment. The inlet air temperature was 50℃, the wind speed was 1.5m / s, the spray pressure was 0.8MPa, and the encapsulation rate was 86%.

[0083] (4) Granulation: The microencapsulated complex is mixed with maltose solution to form granules, dried and then granulated to obtain granules (moisture content 4.2%, particle size passing through a 16-mesh sieve).

[0084] Comparative Example 3

[0085] The composition of this comparative formula is as follows:

[0086] 15 parts of Ganoderma lucidum extract (12.5% ​​Ganoderma lucidum triterpenoid content), 20 parts of Hericium erinaceus extract (93.0% purity of β-glucan), 10 parts of Poria cocos polysaccharide, 7 parts of Auricularia auricula polysaccharide, 25 parts of small molecule protein peptides (whey protein hydrolysate with a molecular weight ≤3kDa), and 15 parts of maltose.

[0087] The weight ratio of Ganoderma lucidum extract to Hericium erinaceus extract was 1:1.33; the weight ratio of total polysaccharide to small molecule protein peptide was 1:0.70.

[0088] Its preparation method includes the following steps:

[0089] (1) Preparation of Ganoderma lucidum extract: Ganoderma lucidum fruiting body was crushed to 60 mesh, extracted twice by reflux with 70% ethanol, the filtrates were combined and concentrated under reduced pressure to obtain atomized liquid with a Ganoderma lucidum triterpenoid concentration of 12.5%.

[0090] (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of 4.5% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain an extract with a β-glucan purity of 93.0%.

[0091] (3) Synergistic activation of complex polysaccharides: Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide were mixed and added with sodium citrate buffer at pH 5.4. At 45°C, 1.5 U / g of cellulase and pectinase were added as substrates and enzymatically hydrolyzed for 120 minutes. After inactivation, the mixture was spray-dried at an inlet air temperature of 180°C and an outlet air temperature of 80°C to obtain complex polysaccharide powder with a water content of 2.8%.

[0092] (4) Microencapsulation coupling: Small molecule protein peptides, compound polysaccharide powder, and Ganoderma lucidum extract atomized liquid are treated in a fluidized bed with an inlet air temperature of 60℃, an air velocity of 2.0m / s, a spray pressure of 1.0MPa, and an encapsulation rate of 70%.

[0093] (5) Granulation: The microencapsulated complex is mixed with maltose solution and granulated. After drying, the granules are sized to obtain granules (moisture content 4.2%, particle size passing through a 16-mesh sieve).

[0094] Experiment 1: Experiment on the repair effect on gastric mucosal damage

[0095] Experimental subjects: Sixty SPF-grade SD rats were randomly divided into 6 groups of 10 each, namely Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2, and Comparative Example 3. A blank control group of 10 rats was also set up and administered physiological saline.

[0096] Experimental methods: Except for the blank control group, rats in all other groups were given ethanol by gavage to establish an acute gastric mucosal injury model.

[0097] After modeling, each experimental group was administered the corresponding compound formula granule aqueous solution by gavage at a dose of 1.0 g / kg body weight, while the blank control group was administered an equal volume of physiological saline by gavage. This was done once daily for 7 consecutive days. Twenty-four hours after the last administration, the rats were sacrificed, and gastric tissue was collected to observe gastric mucosal damage and calculate the gastric mucosal damage index (total ulcer area).

[0098] Table 1 Experimental Data for Experiment 1

[0099] Group <![CDATA[Gastric mucosal injury index (mm 2 )]]> Blank control group 35.2±4.5 Example 1 Group 8.5±1.2 Example 2 group 8.5±1.2 Example 3 Group 7.8±1.0 Comparative Example 1 22.3±3.1 Comparative Example 2 18.5±2.8 Comparative Example 3 Groups 16.7±2.5

[0100] Conclusion: The gastric mucosal damage index of the groups in Examples 1-3 was significantly lower than that of the comparative groups and the blank control group, indicating that the compound formulation of the present invention has a better repair effect on gastric mucosal damage.

[0101] Experiment 2: Experiment to Promote Gastric Motility

[0102] Experimental subjects: Sixty SPF-grade ICR mice were randomly divided into 6 groups of 10 mice each, with the grouping method being the same as in Experiment 1. A blank control group of 10 mice was also set up and administered physiological saline.

[0103] Experimental methods: Each experimental group was administered the corresponding compound formula granule aqueous solution by gavage at a dose of 0.8 g / kg body weight, while the blank control group was administered an equal volume of physiological saline by gavage. This was done once daily for 14 consecutive days. One hour after the last administration, mice in each group were administered ink by gavage (0.1 ml / 10 g body weight). Mice were sacrificed 20 minutes later, their stomachs were removed, and the ink residue rate in the stomach was calculated (residual ink in the stomach / total amount of ink administered by gavage × 100%).

[0104] Table 2 Experimental Data for Experiment 2

[0105] Group Ink residue rate in the stomach (%) Blank control group 65.3±5.2 Example 1 Group 28.5±3.1 Example 2 group 32.1±3.5 Example 3 Group 26.8±2.8 Comparative Example 1 48.6±4.2 Comparative Example 2 43.2±3.8 Comparative Example 3 Groups 40.5±3.5

[0106] Conclusion: The residual rate of ink in the stomach of the groups in Examples 1-3 was significantly lower than that of the comparative groups and the blank control group, indicating that the compound formulation of the present invention can more effectively promote gastric motility and improve gastric digestive function.

[0107] The present invention and its embodiments have been described above. This description is not restrictive. In short, if a person skilled in the art is inspired by this description and designs a similar structure and embodiment without departing from the spirit of the present invention, such design should fall within the protection scope of the present invention.

Claims

1. A compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health benefits, characterized in that, It consists of the following raw materials in parts by weight: 10-20 parts of Ganoderma lucidum extract, 15-25 parts of Hericium erinaceus extract, 8-15 parts of Poria cocos polysaccharide, 5-10 parts of Auricularia auricula polysaccharide, 20-30 parts of small molecule protein peptides, and 10-20 parts of maltose; Wherein: the Ganoderma lucidum extract contains ≥12% Ganoderma lucidum triterpenes; the Hericium erinaceus extract contains ≥92.7% β-glucan; and the small molecule protein peptide is a whey protein hydrolysate with a molecular weight ≤3kDa.

2. The compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health function according to claim 1, characterized in that, The weight ratio of Ganoderma lucidum extract to Hericium erinaceus extract is 1:1 to 2; the weight ratio of total complex polysaccharide to small molecule protein peptide is 1:0.5 to 2.0; wherein the total complex polysaccharide is the sum of Poria cocos polysaccharide, Auricularia auricula polysaccharide and β-glucan in Hericium erinaceus extract.

3. The compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health function according to claim 1, characterized in that, Its dosage form is granules, and the moisture content of the granules is ≤5%, and the particle size passes through a 16-mesh sieve.

4. A method for preparing a compound formula of Ganoderma lucidum and Hericium erinaceus with stomach health care function according to any one of claims 1-3, characterized in that, Includes the following steps: (1) Preparation of Ganoderma lucidum extract: The fruiting bodies of Ganoderma lucidum were crushed to 60 mesh and extracted twice by reflux with 70% ethanol. The filtrates were combined and concentrated under reduced pressure to obtain an atomized liquid with a Ganoderma lucidum triterpenoid concentration of ≥12%. (2) Preparation of Hericium erinaceus extract: Hericium erinaceus was freeze-dried to a moisture content of ≤5% and then ultra-finely pulverized. The extract was purified by gradient centrifugation to obtain Hericium erinaceus extract with a β-glucan purity of ≥92.7%. (3) Synergistic activation by complex polysaccharides: The Hericium erinaceus extract, Poria cocos polysaccharide and Auricularia auricula polysaccharide obtained in step (2) were mixed and added to sodium citrate buffer solution with pH=5.

4. Enzymatic hydrolysis was carried out at 45℃ using cellulase and pectinase. After enzymatic hydrolysis, the polysaccharide was inactivated and spray-dried to obtain a composite polysaccharide powder with a water content of ≤3%. (4) Microencapsulation coupling: The small molecule protein peptides, the composite polysaccharide powder obtained in step (3), and the Ganoderma lucidum extract atomized liquid obtained in step (1) were microencapsulated in a fluidized bed, with an encapsulation rate ≥85%. (5) Granulation: The microencapsulated complex obtained in step (4) is mixed with maltose solution to form granules, dried and then granulated to obtain granules.

5. The preparation method according to claim 4, characterized in that, In step (3), the enzymatic hydrolysis conditions are: 1.5 U / g of substrate is added for each of cellulase and pectinase, and the enzymatic hydrolysis time is 120 minutes; the spray drying parameters are: inlet air temperature 180±5℃, outlet air temperature 80±5℃.

6. The preparation method according to claim 4, characterized in that, In step (4), the fluidized bed parameters are: inlet air temperature 50±2℃, air velocity 1.5±0.2m / s, spray pressure 0.8±0.1MPa; after microencapsulation, the encapsulation rate is detected by microcolumn centrifugation at 3000rpm×10min.